Illumina, Inc. $ILMN Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 14,627,880 shares of the life sciences company’s stock after selling 525,153 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Illumina worth $1,389,210,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Empowered Funds LLC increased its holdings in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina in the second quarter valued at $621,000. Nordea Investment Management AB raised its holdings in shares of Illumina by 14.2% in the 2nd quarter. Nordea Investment Management AB now owns 13,138 shares of the life sciences company’s stock valued at $1,265,000 after buying an additional 1,633 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Illumina by 0.3% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 102,344 shares of the life sciences company’s stock worth $9,617,000 after acquiring an additional 295 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new position in Illumina during the 2nd quarter valued at about $41,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.60% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $117.67 on Friday. The stock has a market cap of $17.99 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 2.30 and a beta of 1.45. The company has a fifty day simple moving average of $135.80 and a 200-day simple moving average of $117.07. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the firm posted $0.95 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. JPMorgan Chase & Co. reduced their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Stifel Nicolaus increased their target price on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. UBS Group restated a “neutral” rating and issued a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Finally, Guggenheim lifted their target price on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $127.94.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.